Methylphenidate selectively modulates one sub-component of the no-go P3 in pediatric ADHD medication responders

Ida Emilia Aasen; Geir Øgrim; Juri Kropotov; Jan Ferenc Brunner

doi:10.1016/j.biopsycho.2018.02.011

Methylphenidate selectively modulates one sub-component of the no-go P3 in pediatric ADHD medication responders

Biol Psychol. 2018 Apr:134:30-38. doi: 10.1016/j.biopsycho.2018.02.011. Epub 2018 Feb 21.

Authors

Ida Emilia Aasen¹, Geir Øgrim², Juri Kropotov³, Jan Ferenc Brunner⁴

Affiliations

¹ Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway; Department of Neuropsychology, Helgeland Hospital, Mosjøen, Norway. Electronic address: ida.aasen@ntnu.no.
² Department of Psychology, Norwegian University of Science and Technology, Trondheim, Norway; Neuropsychiatric Unit, Østfold Hospital Trust, Fredrikstad, Norway.
³ N.P. Bechtereva Institute of the Human Brain, Russian Academy of Sciences, St. Petersburg, Russia; Department of Neuropsychology, Andrzej Frycz-Modrzewski Krakow University, Krakow, Poland.
⁴ Department of Neuropsychology, Helgeland Hospital, Mosjøen, Norway.

PMID: 29476840
DOI: 10.1016/j.biopsycho.2018.02.011

Abstract

Methylphenidate (MPH) has been shown to modulate the amplitude of the no-go P3 component of the event-related potential (ERP; Øgrim, Aasen, & Brunner, 2016). Using group independent component analysis, the no-go P3 from a cued go/no-go task has been separated into two sub-components (Brunner et al., 2013). This study investigated whether sub-components of the no-go P3 could be identified in children with ADHD, and how MPH modulates their amplitudes. ERPs were registered twice (on/off MPH) in 57 children with ADHD classified as medication responders in a four-week medication trial. Two no-go P3 sub-components were identified. In the MPH session, the amplitude of one sub-component, the IC P3no-go_early (mean latency 378 ms, with a central distribution), was significantly larger than at baseline, whereas the other sub-component, the IC P3no-go_late (mean latency 428 ms, with a centro-frontal distribution), was not significantly affected. These results add to the literature documenting that the no-go P3 consists of two overlapping phenomena with different functional correlates.

Trial registration: ClinicalTrials.gov NCT02695355.

Keywords: ADHD; Cued go/no-go; ICA; MPH; No-go P3.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Attention Deficit Disorder with Hyperactivity / drug therapy*
Attention Deficit Disorder with Hyperactivity / psychology
Central Nervous System Stimulants / pharmacology*
Central Nervous System Stimulants / therapeutic use
Child
Electroencephalography / drug effects*
Evoked Potentials / drug effects
Female
Humans
Male
Methylphenidate / pharmacology*
Methylphenidate / therapeutic use
Principal Component Analysis
Psychomotor Performance / drug effects
Treatment Outcome

Substances

Central Nervous System Stimulants
Methylphenidate

Associated data

ClinicalTrials.gov/NCT02695355